800% Dividend Payout: Largecap Pharma Stock In Focus Amid Stock Split Consideration; Should You Buy?

Dr Reddy's Laboratories, one of India's leading pharmaceutical companies, is poised for a corporate move. The board of directors will convene on Saturday, July 27, to deliberate on a proposal to split the company's equity shares. Currently, each share of Dr Reddy's has a face value of Rs 5, marking the first time the company will conduct a stock split since becoming a public entity.

This proposal, if approved, will also encompass American Depository Shares (ADRs), reflecting Dr Reddy's commitment to maintaining shareholder value across global markets. The split is contingent upon the approval of the company's shareholders, who will have the final say in this transformative decision.

This meeting comes on the back of Dr Reddy's recent strategic acquisition announcement. Last month, Dr Reddy's Laboratories SA, a subsidiary of the company, entered into a definitive agreement with Haleon plc and its associates. This agreement focuses on acquiring a global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category, excluding the United States.

The acquisition involves the purchase of shares of Northstar Switzerland SARL, a Haleon group company. Dr. Reddy's will acquire the share capital of Northstar Switzerland SARL for a total consideration of GBP 500 million. The transaction includes an upfront cash payment of GBP 458 million, complemented by performance-based contingent payments of up to GBP 42 million, payable in 2025 and 2026. This acquisition is set to bolster Dr Reddy's presence in the global consumer healthcare market.

Despite these strategic moves, Dr Reddy's recent financial performance has been a mixed bag. The company's earnings for the March quarter fell short of market expectations. The drugmaker reported an EBITDA margin of 26.4% for the quarter, a figure that, while robust, did not meet analyst forecasts.

The market sentiment reflected this financial performance. As of 9:40 am on the National Stock Exchange (NSE), shares of Dr Reddy's were trading with a slight decline of nearly 1%, priced at Rs 6,824.75 per share. Despite this dip, the stock has demonstrated resilience and growth, delivering returns of nearly 30% over the past year.

The proposed stock split is expected to make Dr Reddy's shares more accessible to a broader base of investors, potentially enhancing liquidity and marketability. This move, coupled with the strategic acquisition in the NRT category, reflects Dr Reddy's approach to expanding its market footprint and enhancing shareholder value.

Shareholders and market analysts will be watching the upcoming board meeting and subsequent shareholder decisions, which could set the stage for Dr Reddy's next phase of growth.